secwatch.observer — SEC 8-K summary
======================================

Issuer:     Processa Pharmaceuticals, Inc. (PCSA)
CIK:        0001533743
Form:       8-K
Filed at:   2024-01-19T23:59:59+00:00
Accession:  0001493152-24-002983
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Processa expands NGC-Cap into breast cancer; FDA agrees existing data supports Phase 2 trial
--------------------------------------------------------------------------------

- FDA agreed existing data can directly support Phase 2 breast cancer trial design.
- Plan to initiate Phase 2 study in advanced/metastatic breast cancer in Q3 2024.
- Breast cancer represents larger market than colorectal; potential for >250,000 patients/year.
- Company identified breast cancer KOLs for scientific advisory board.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1533743/000149315224002983/0001493152-24-002983-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1533743/000149315224002983/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-002983

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer